Fuller & Thaler Asset Management Inc. Lowers Position in ICU Medical, Inc. $ICUI

Key Points

• Fuller & Thaler Asset Management Inc. holds a $192.07 million stake in ICU Medical, Inc., accounting for 0.7% of its portfolio after reducing its holdings by 0.8% in the first quarter.
• CEO Vivek Jain purchased 21,929 shares for approximately $2.47 million, representing a 20.26% increase in his ownership, while COO Christian B. Voigtlander sold 4,985 shares.
• ICU Medical reported an EPS of $2.10 for the last quarter, exceeding expectations, but revenues decreased by 8.0% year-over-year, indicating challenges despite beating earnings forecasts.

Fuller & Thaler Asset Management Inc. cut its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 0.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,383,223 shares of the medical instruments supplier's stock after selling 11,455 shares during the quarter. ICU Medical makes up about 0.7% of Fuller & Thaler Asset Management Inc.'s investment portfolio, making the stock its 26th largest position. Fuller & Thaler Asset Management Inc. owned approximately 5.62% of ICU Medical worth $192,074,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Quarry LP lifted its stake in ICU Medical by 764.3% in the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 214 shares during the period. Russell Investments Group Ltd. lifted its stake in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 300 shares during the period. GAMMA Investing LLC lifted its stake in ICU Medical by 27.2% in the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 153 shares during the period. Sterling Capital Management LLC lifted its stake in ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock worth $105,000 after acquiring an additional 602 shares during the period. Finally, Blue Trust Inc. lifted its stake in ICU Medical by 23.0% in the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after acquiring an additional 150 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

NASDAQ:ICUI traded up $6.43 during midday trading on Friday, hitting $128.18. The company's stock had a trading volume of 275,297 shares, compared to its average volume of 376,418. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $196.26. The firm's 50 day moving average is $127.17 and its 200-day moving average is $137.05. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The firm has a market cap of $3.16 billion, a P/E ratio of -84.33 and a beta of 0.88.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, topping the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. During the same quarter in the prior year, the company earned $1.56 EPS. ICU Medical's quarterly revenue was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 4,985 shares of the company's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the sale, the chief operating officer owned 6,088 shares in the company, valued at approximately $782,308. This represents a 45.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction on Thursday, August 14th. The stock was bought at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on ICUI. Raymond James Financial lowered their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. Piper Sandler started coverage on shares of ICU Medical in a report on Friday, August 15th. They issued an "overweight" rating and a $145.00 target price for the company. Finally, Wall Street Zen downgraded shares of ICU Medical from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $179.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.